WAY-102 / Waypoint Bio - LARVOL DELTA

WAY-102: An in vivo lentiviral dual-armored CLDN18.2 CAR T engineered for long-term durability & cytotoxicity in the tumor microenvironment (SITC 2025) - "Mechanistically, we show that the armors in WAY-102 increase T cell infiltration-capacity, cytotoxicity, and expansion. To develop an off-the-shelf treatment with WAY-102, we used an engineered lentivirus for in vivo CAR T manufacturing, which specifically transduced WAY-102 into T cells in PBMC-humanized mice and resulted in complete CLDN18.2+ tumor clearance.Conclusions WAY-102 CAR T cells show promising anti-tumor efficacy against multiple in vivo CLDN18.2+ solid tumor models, with successful in vivo manufacturing of WAY-102 paving the way for an off-the-shelf therapy for CLDN18.2+ cancers.Ethics Approval All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Mispro Biotech Services, under the approved protocols 2023-WPT-01 (amendments A1-A20) and 2024-WPT-02."

Preclinical • Tumor microenvironment • Gastric Cancer • Oncology • Pancreatic Cancer • Peritoneal Cancer • Solid Tumor • CLDN18 • IL15 • TGFB1